

P19850.P01

**UTILITY  
PATENT APPLICATION  
TRANSMIT**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	P19850	Total Pages
Inventor(s) or Applicant Identifier:	Dipak K. BANERJEE and Juan A. MARTÍNEZ	
Title:	METHODS FOR INHIBITING ANGIOGENESIS	
	JCE41 179447 pro 09/09/01	

ADDRESS TO:

**Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231**

APPLICATION ELEMENTS		ACCOMPANYING APPLICATION PARTS	
1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)		9. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)	
2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		a. <input type="checkbox"/> Computer Readable Form (CRF)	
a. <input type="checkbox"/> Small Entity Statement(s)		b. Specification Sequence Listing on:	
		i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or	
		ii. <input type="checkbox"/> paper	
		c. <input type="checkbox"/> Statements verifying identity of above copies	
3. <input checked="" type="checkbox"/> Specification (preferred arrangement set forth below)	[Total Pages 79 ]	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	
- Descriptive title of the Invention		11. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee)	<input type="checkbox"/> Power of Attorney
- Cross References to Related Applications		12. <input type="checkbox"/> English Translation Document (if applicable)	
- Statement Regarding Fed sponsored R & D		13. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/> Copies of IDS Citations
- Reference to sequence listing, a table, or a computer program listing appendix		14. <input type="checkbox"/> Preliminary Amendment	
- Background of the Invention		15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
- Brief Summary of the Invention		16. <input checked="" type="checkbox"/> Figure of Drawing to be published <u>3a</u>	
- Brief Description of the Drawings (if filed)		17. <input type="checkbox"/> Foreign priority claimed	
- Detailed Description		a. <input type="checkbox"/> Claim of Priority	
- Claim(s)		b. <input type="checkbox"/> Certified Copy of Priority Document(s)	
- Abstract of the Disclosure		18. <input type="checkbox"/> Assignee: _____	
4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113)	[Total Sheets 19 ]	19. <input checked="" type="checkbox"/> Other: <u>Cover Letter Under 37 C.F.R. 1.53(b) and 1.53(f)</u>	
5. <input checked="" type="checkbox"/> Oath or Declaration	[Total Pages 3 ]		
a. <input type="checkbox"/> Newly executed (original or copy)	<input checked="" type="checkbox"/> Unexecuted		
b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20 completed)			
	[Note Box 6 below]		
i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>			
	Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		
6. <input type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked)			
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.			
7. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76			
8. <input type="checkbox"/> CD-Rom or CD-R in duplicate, large table or Computer Program (Appendix)			
20. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:			
<input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No. _____ / _____, filed _____ Prior application information: Examiner: _____ Group Art Unit: _____			
21. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application is a _____ continuation-in-part, _____ continuation, _____ divisional, of Application No. _____ / _____, filed _____			

Address all future correspondence to **Customer No. 7055** at the present address of:

GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Feb. 09, 2001  
Date

  
Signature  
Reyns 2/09/01

Arnold Turk, Reg. No. 33,094  
Typed or Printed Name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dipak K. BANERJEE et al.

Serial No : Not Yet Assigned

Filed : Concurrently Herewith

For : METHODS FOR INHIBITING ANGIOGENESIS

COVER LETTER ACCOMPANYING U.S. PATENT APPLICATION  
FILED UNDER 37 C.F.R. 1.53(b)and 1.53(f)

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Enclosed is a new patent application for filing in the U.S. Patent and Trademark Office under 37 C.F.R. 1.53(b)and 1.53(f) in which the Declaration and Power of Attorney attached thereto are in unexecuted form. An executed Declaration and Power of Attorney will be filed within the time period set forth in the Notice to File Missing Parts of Application, unless such time period has been extended by the filing of a petition accompanied by the extension fee under the provisions of 37 C.F.R. 1.136(a).

Related to this, a correspondence address is provided in the unexecuted Declaration and Power of Attorney, and is as follows:


GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, Va. 20191

The above-identified application includes:

- 79 pages of specification (including Abstract);
- 92 total claims; with 18 independent;
- 19 sheets of drawings with 42 figures;
- an unexecuted Declaration and Power of Attorney.

If there are any questions, please contact the undersigned at the below-listed telephone number.

Respectfully submitted,  
Dipak K. BANERJEE et al.

  
Arnold Turk  
Reg. No. 33,094 *Key No.  
31,226*

GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, Va. 20191  
(703) 716-1191